|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
CN107501407B
(zh)
|
2007-03-30 |
2022-03-18 |
Ambrx公司 |
经修饰fgf-21多肽和其用途
|
|
ES2692495T3
(es)
|
2009-01-23 |
2018-12-03 |
Novo Nordisk A/S |
Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
|
|
WO2011154349A2
(en)
*
|
2010-06-08 |
2011-12-15 |
Novo Nordisk A/S |
Fgf21 analogues and derivatives
|
|
EP2359843A1
(en)
*
|
2010-01-21 |
2011-08-24 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
CN103124562A
(zh)
*
|
2010-06-08 |
2013-05-29 |
诺沃—诺迪斯克有限公司 |
Fgf21的类似物和衍生物
|
|
US8951966B2
(en)
|
2011-07-01 |
2015-02-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
|
|
EP2548570A1
(en)
*
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
|
CN104203977A
(zh)
|
2012-02-15 |
2014-12-10 |
诺和诺德A/S(股份有限公司) |
结合肽聚糖识别蛋白1的抗体
|
|
WO2013120553A1
(en)
|
2012-02-15 |
2013-08-22 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
AR092076A1
(es)
*
|
2012-08-22 |
2015-03-18 |
Lilly Co Eli |
Proteinas homodimericas
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
WO2014085365A2
(en)
|
2012-11-28 |
2014-06-05 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
CA2895875A1
(en)
|
2012-12-21 |
2014-06-26 |
Sanofi |
Exendin-4 derivatives
|
|
DK2938740T3
(da)
|
2012-12-27 |
2022-06-20 |
Ngm Biopharmaceuticals Inc |
Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
ES2646538T3
(es)
|
2013-06-20 |
2017-12-14 |
Novo Nordisk A/S |
Derivados de GLP-1 y sus usos
|
|
WO2015065897A1
(en)
|
2013-10-28 |
2015-05-07 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
EP3080150B1
(en)
|
2013-12-13 |
2018-08-01 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
CN106662577B
(zh)
|
2014-01-24 |
2020-07-21 |
恩格姆生物制药公司 |
结合蛋白及其使用方法
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
|
TW201625668A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
SG11201700250WA
(en)
|
2014-07-17 |
2017-02-27 |
Novo Nordisk As |
Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
|
|
WO2016065106A1
(en)
|
2014-10-23 |
2016-04-28 |
Ngm Biopharmaceuticals, Inc. |
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
ES2739289T3
(es)
|
2014-11-27 |
2020-01-30 |
Novo Nordisk As |
Derivados de GLP-1 y sus usos
|
|
CN107108714B
(zh)
|
2014-12-17 |
2022-02-08 |
诺和诺德股份有限公司 |
Glp-1衍生物及其用途
|
|
HK1246156B
(en)
|
2014-12-23 |
2020-03-27 |
Novo Nordisk A/S |
FGF21 derivatives and their uses
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
EP3331557B1
(en)
|
2015-08-04 |
2021-04-07 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
KR102668200B1
(ko)
|
2015-10-28 |
2024-05-23 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
|
KR102670157B1
(ko)
*
|
2015-10-28 |
2024-05-29 |
주식회사유한양행 |
이중 작용 단백질 및 이를 포함하는 약학적 조성물
|
|
WO2017083276A1
(en)
|
2015-11-09 |
2017-05-18 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
US11318186B2
(en)
|
2016-05-25 |
2022-05-03 |
Board Of Regents, The University Of Texas System |
Use of FGF21 in methods of increasing exocrine pancreatic secretion
|
|
US11467156B2
(en)
|
2016-06-01 |
2022-10-11 |
Duke University |
Nonfouling biosensors
|
|
US11123438B2
(en)
|
2016-08-19 |
2021-09-21 |
Ampsource Biopharma Shanghai Inc. |
Linker peptide for constructing fusion protein
|
|
CN107759696A
(zh)
|
2016-08-19 |
2018-03-06 |
安源医药科技(上海)有限公司 |
人白介素7融合蛋白及其制备方法
|
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
US11135301B2
(en)
|
2016-09-14 |
2021-10-05 |
Duke University |
Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
|
|
WO2018057847A1
(en)
|
2016-09-23 |
2018-03-29 |
Duke University |
Unstructured non-repetitive polypeptides having lcst behavior
|
|
BR112019009581A2
(pt)
|
2016-11-10 |
2019-10-08 |
Yuhan Corp |
composição farmacêutica para evitar ou tratar hepatite, fibrose hepática, e cirrose hepática que compreende proteínas de fusão
|
|
JP7097380B2
(ja)
*
|
2016-11-25 |
2022-07-07 |
ベケッド、フレデリク |
代謝性障害
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
WO2018166461A1
(en)
|
2017-03-14 |
2018-09-20 |
Sunshine Lake Pharma Co., Ltd. |
Dual-target fusion proteins comprising the fc portion of an immunoglobulin
|
|
CN108619490A
(zh)
*
|
2017-03-22 |
2018-10-09 |
天士力医药集团股份有限公司 |
一种长效化突变的人源成纤维生长因子的新用途
|
|
MX2019012331A
(es)
|
2017-04-21 |
2020-01-23 |
Yuhan Corp |
Metodo para producir proteinas de doble funcion y sus derivados.
|
|
US11554097B2
(en)
|
2017-05-15 |
2023-01-17 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
WO2019006374A1
(en)
|
2017-06-30 |
2019-01-03 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
|
|
CN115109166B
(zh)
*
|
2017-11-24 |
2025-07-18 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
US11752173B2
(en)
|
2017-12-19 |
2023-09-12 |
Beijing Jiyuan Biological Technology Co., Ltd. |
FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
|
|
CN109942696A
(zh)
*
|
2017-12-21 |
2019-06-28 |
中国药科大学 |
长效化胰高血糖素样肽-1(glp-1)类似物及其应用
|
|
CN113603794B
(zh)
*
|
2018-01-11 |
2024-01-16 |
安源医药科技(上海)有限公司 |
用于调节血糖和脂质的增效型双功能蛋白
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
EP3749683A4
(en)
|
2018-02-08 |
2022-03-16 |
Sunshine Lake Pharma Co., Ltd. |
FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
|
|
CA3092387A1
(en)
|
2018-04-02 |
2019-10-10 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
|
EP3788343B1
(en)
|
2018-04-30 |
2024-03-27 |
Duke University |
Stimuli-responsive peg-like polymer-based drug delivery platform
|
|
EP3829622A4
(en)
|
2018-08-02 |
2022-05-11 |
Duke University |
DOUBLE AGONIST FUSION PROTEINS
|
|
AU2020256648A1
(en)
*
|
2019-04-11 |
2021-11-04 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Multi-receptor agonist and medical use thereof
|
|
CN114853908B
(zh)
|
2019-05-16 |
2024-06-07 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
CN112279920B
(zh)
*
|
2019-07-25 |
2024-01-16 |
安源医药科技(上海)有限公司 |
FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
|
|
WO2021139744A1
(en)
|
2020-01-11 |
2021-07-15 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Conjugates of fusion proteins of glp-1 and fgf21
|
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
KR20250167609A
(ko)
|
2023-03-30 |
2025-12-01 |
노보 노르디스크 에이/에스 |
융합 화합물 및 그 용도
|
|
WO2025125576A2
(en)
|
2023-12-15 |
2025-06-19 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025133348A1
(en)
|
2023-12-22 |
2025-06-26 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025196502A1
(en)
|
2024-03-20 |
2025-09-25 |
North Carolina Agricultural & Technical State University |
Choline kinase inhibitors as a therapeutic treatment for obesity
|